Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?

Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?

Key PointsNovo Nordisk was the first to market with a GLP-1 weight-loss drug. It lost its early lead to Eli Lilly, which is now the name to beat in the GLP-1 race.Novo Nordisk is attempting to make a comeback with its hugely popular Wegovy pill. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) kicked off a revolutionary shift in how obesity is treated. The goal, at first, was to help diabetics deal with weight loss, but the …